

## Kim, Sabrina

---

**From:** Kim, Sabrina  
**Sent:** Monday, September 28, 2020 5:33 PM  
**To:** Gerasimov, Boyan (SPAC/PSPC)  
**Cc:** Hage-Moussa, Vanessa; Newman, Leo (HC/SC); Lamothe, Colleen; fitz-morris, James (SPAC/PSPC); MacKendrick, Andrew; Theis, Rick; Holland, Alyx; Nowers, Kathryn (HC/SC); Bélair, Thierry (HC/SC) ; Roy, Cecely (SPAC/PSPC); Sambasivam, Bud; Lemkay, Kevin  
**Subject:** Re: Abbott announcement on Tuesday.

Thanks! Adding Kev too.

> On Sep 28, 2020, at 5:01 PM, Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca> wrote:  
>  
> For awareness, the WHO just did a big deal to buy the Abbott Panbio. This is the next item in our talks with Abbott. Also useful news the day before we announce a deal with Abbott ourselves.  
>  
> <https://www.who.int/news-room/detail/28-09-2020-global-partnership-to-make-available-120-million-affordable-quality-covid-19-rapid-tests-for-low-and-middle-income-countries>  
>  
> Boyan Gerasimov  
> Director of Policy | Directeur des politiques Office of the Minister  
> of Public Services and Procurement | Cabinet de la ministre des  
> Services publics et Approvisionnement Canada  
>  
>  
> -----Original Message-----  
> From: Hage-Moussa, Vanessa [mailto:Vanessa.Hage-Moussa@pmo-cpm.gc.ca]  
> Sent: Monday, September 28, 2020 4:00 PM  
> To: Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca>; Newman, Leo (HC/SC) <leo.newman@canada.ca>  
> Cc: Lamothe, Colleen <Colleen.Lamothe@pmo-cpm.gc.ca>; fitz-morris, James (SPAC/PSPC) <james.fitz-morris@canada.ca>; MacKendrick, Andrew <Andrew.MacKendrick@pmo-cpm.gc.ca>; Theis, Rick <Rick.Theis@pmo-cpm.gc.ca>; Holland, Alyx <alyx.holland@pmo-cpm.gc.ca>; Kim, Sabrina <Sabrina.Kim@pmo-cpm.gc.ca>; Nowers, Kathryn (HC/SC) <kathryn.nowers@canada.ca>; Bélair, Thierry (HC/SC) <thierry.belair@canada.ca>; Roy, Cecely (SPAC/PSPC) <cecely.roy@canada.ca>  
> Subject: RE: Abbott announcement on Tuesday.  
>  
> Hey guys - so even though the regulatory approval piece is not landed yet, we will proceed with announcing the Abbott procurement piece. This in line with what we've been doing on vaccines and therapeutics like AbCellera. Messaging being: If and when this is approved and safe for use, we will be ready.  
>  
> Messaging in the tech briefing will be key to contextualizing Canada's  
> pace in approving things compared to other jurisdictions  
>

> -----Original Message-----

> From: Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca>

> Sent: Monday, September 28, 2020 1:23 PM

> To: Newman, Leo (HC/SC) <leo.newman@canada.ca>; Hage-Moussa, Vanessa

> <Vanessa.Hage-Moussa@pmo-cpm.gc.ca>

> Cc: Lamothe, Colleen <Colleen.Lamothe@pmo-cpm.gc.ca>; fitz-morris,

> James (SPAC/PSPC) <james.fitz-morris@canada.ca>; MacKendrick, Andrew

> <Andrew.MacKendrick@pmo-cpm.gc.ca>; Theis, Rick

> <Rick.Theis@pmo-cpm.gc.ca>; Holland, Alyx

> <alyx.holland@pmo-cpm.gc.ca>; Kim, Sabrina

> <Sabrina.Kim@pmo-cpm.gc.ca>; Nowers, Kathryn (HC/SC)

> <kathryn.nowers@canada.ca>; Bélair, Thierry (HC/SC)

> <thierry.belair@canada.ca>; Roy, Cecely (SPAC/PSPC)

> <cecely.roy@canada.ca>

> Subject: RE: Abbott announcement on Tuesday.

>

> Just adding Cecely

>

> Boyan Gerasimov

> Director of Policy | Directeur des politiques Office of the Minister

> of Public Services and Procurement | Cabinet de la ministre des

> Services publics et Approvisionnement Canada

>

>

> -----Original Message-----

> From: Newman, Leo (HC/SC)

> Sent: Monday, September 28, 2020 1:22 PM

> To: Hage-Moussa, Vanessa <Vanessa.Hage-Moussa@pmo-cpm.gc.ca>;

> Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca>

> Cc: Lamothe, Colleen <Colleen.Lamothe@pmo-cpm.gc.ca>; fitz-morris,

> James (SPAC/PSPC) <james.fitz-morris@canada.ca>; MacKendrick, Andrew

> <Andrew.MacKendrick@pmo-cpm.gc.ca>; Theis, Rick

> <Rick.Theis@pmo-cpm.gc.ca>; Holland, Alyx

> <alyx.holland@pmo-cpm.gc.ca>; Kim, Sabrina

> <Sabrina.Kim@pmo-cpm.gc.ca>; Nowers, Kathryn (HC/SC)

> <kathryn.nowers@canada.ca>; Bélair, Thierry (HC/SC)

> <thierry.belair@canada.ca>

> Subject: RE: Abbott announcement on Tuesday.

>

> Latest update from HC officials:

>

> Abbott (ID NOW v.1.0) (US FDA authorized, manufactured in USA)

> - Company provided response to last request for information on September 24.

> - A teleconference with Abbott will be quickly organized to discuss  
> the issues

>

> We'll circle back as soon as we hear anything else.

>

> -----Original Message-----

> From: Hage-Moussa, Vanessa <Vanessa.Hage-Moussa@pmo-cpm.gc.ca>

> Sent: 2020-09-28 9:51 AM

> To: Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca>



> Cc: Lamothe, Colleen <Colleen.Lamothe@pmo-cpm.gc.ca>; fitz-morris,  
> James (SPAC/PSPC) <james.fitz-morris@canada.ca>; MacKendrick, Andrew  
> <Andrew.MacKendrick@pmo-cpm.gc.ca>; Theis, Rick  
> <Rick.Theis@pmo-cpm.gc.ca>; Holland, Alyx  
> <alyx.holland@pmo-cpm.gc.ca>; Kim, Sabrina  
> <Sabrina.Kim@pmo-cpm.gc.ca>; Nowers, Kathryn (HC/SC)  
> <kathryn.nowers@canada.ca>; Newman, Leo (HC/SC)  
> <leo.newman@canada.ca>; Bélair, Thierry (HC/SC)  
> <thierry.belair@canada.ca>  
> Subject: RE: Abbott announcement on Tuesday.

>  
> Thanks Boyan - adding Thierry here as well  
>  
> HC - how are things going on the approval side?  
>

> -----Original Message-----

> From: Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca>  
> Sent: Monday, September 28, 2020 9:04 AM  
> To: Hage-Moussa, Vanessa <Vanessa.Hage-Moussa@pmo-cpm.gc.ca>  
> Cc: Lamothe, Colleen <Colleen.Lamothe@pmo-cpm.gc.ca>; fitz-morris,  
> James (SPAC/PSPC) <james.fitz-morris@canada.ca>; MacKendrick, Andrew  
> <Andrew.MacKendrick@pmo-cpm.gc.ca>; Theis, Rick  
> <Rick.Theis@pmo-cpm.gc.ca>; Holland, Alyx  
> <alyx.holland@pmo-cpm.gc.ca>; Kim, Sabrina  
> <Sabrina.Kim@pmo-cpm.gc.ca>; Nowers, Kathryn (HC/SC)  
> <kathryn.nowers@canada.ca>; Newman, Leo (HC/SC) <leo.newman@canada.ca>  
> Subject: RE: Abbott announcement on Tuesday.

>  
> Minister Anand has just approved the contract, so we are good to go on that end. Details below. James should be able to advise what is going in the speaking notes.

>  
> Boyan  
>  
> Boyan Gerasimov  
> Director of Policy | Directeur des politiques Office of the Minister  
> of Public Services and Procurement | Cabinet de la ministre des  
> Services publics et Approvisionnement Canada  
>

> -----Original Message-----

> From: Hage-Moussa, Vanessa [mailto:Vanessa.Hage-Moussa@pmo-cpm.gc.ca]  
> Sent: Monday, September 28, 2020 8:56 AM  
> To: Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca>  
> Cc: Lamothe, Colleen <Colleen.Lamothe@pmo-cpm.gc.ca>; fitz-morris,  
> James (SPAC/PSPC) <james.fitz-morris@canada.ca>; MacKendrick, Andrew  
> <Andrew.MacKendrick@pmo-cpm.gc.ca>; Theis, Rick  
> <Rick.Theis@pmo-cpm.gc.ca>; Holland, Alyx  
> <alyx.holland@pmo-cpm.gc.ca>; Kim, Sabrina  
> <Sabrina.Kim@pmo-cpm.gc.ca>; Nowers, Kathryn (HC/SC)  
> <kathryn.nowers@canada.ca>; Newman, Leo (HC/SC) <leo.newman@canada.ca>  
> Subject: Re: Abbott announcement on Tuesday.

>

> Happy Monday all - PSPC/HC grateful if you could advise on any updates on this as of this morning? Will we be on a good place to announce this tomorrow?

>  
> Sent from my iPhone

>  
> On Sep 25, 2020, at 5:15 PM, Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca> wrote:

>  
>  
> Contract pending approval by Minister Anand. Pasting details below that will be partially redundant with the one pager. Let me know if you have specific questions.

>  
> ~~~  
>  
> This contract is based on a requisition by National Microbiology Laboratory and is intended to support the ramp-up of testing capacity by provinces and territories.

>  
> Health Canada has already approved the instrument (which can be used for different respiratory diseases, such as COVID-19, Influenza A, Influenza B, etc.) and is in the process of reviewing the COVID-19 test kits used with this instrument. Would be great to get an update from Kathryn on the status of this process.

>  
> The sole-source contract with a maximum value of \$334.9M has 3 key parts:

>  
>  
>  
> · Firm order of 1,700 analyzers (Health Canada Approved) for \$10.0M (taxes included). This part is not conditional on the approval of the COVID-19 test kits. In the unlikely case that they are not authorized, the devices could be used for testing other respiratory diseases.

>  
>  
>  
> · First option to buy 2.5M test kits and 800 additional analyzers when Abbott receives Health Canada approvals for the test for \$103.5M (taxes included). These supplies are to be delivered between October and December 2020.

>  
>  
>  
> · Second option to buy an additional 5.4M test kits and an additional 1,300 analyzers for \$221.3M (taxes included), which would be exercised once Health Canada obtains additional funding. These supplies are to be delivered in Q1 2021.

>  
> A few key considerations:

>  
>  
>  
> · The requirement for these devices and supplies has been identified by the National Microbiology Laboratory who will be responsible for establishing a protocol for their use and deploying them in PTs. PSPC is executing the contract on their behalf.

>  
>  
> · So far, we have struggled securing meaningful supplies of point-of-care tests. Spartan is unlikely to be approved before November-December 2020, while Cepheid has only managed to fulfill a small portion of our order. Abbott has allocated significant volumes for Canada and has committed to an aggressive delivery schedule that would give us 2.5 million test kits by the end of the year (note that since March, Canada as a whole has conducted just over 6M tests).



>

> · While the Abbott ID Now test has slightly lower accuracy than the lab-based PCR tests or the Cepheid test, the emerging view is that the Abbott test is likely to be used as a screening device that would allow provinces to divert asymptomatic patients away from the increasingly crowded testing centres (PHAC and NML are expected clarify the precise deployment approach shortly). --> Kathryn might be better placed to provide details here

>

>

>

> · The financial risk associated with the test kits not receiving regulatory approval is low, all but \$10M of the contract value is contingent on that approval and the NML can redeploy the analyzer devices even in the highly unlikely case that the accompanying COVID-19 test kits are not approved.

>

>

>

> · This procurement is in line with the very firm public commitment that our government has made to secure access to promising POC testing technologies as they receive regulatory approval.

>

>

> Boyan Gerasimov

> Director of Policy | Directeur des politiques Office of the Minister

> of Public Services and Procurement | Cabinet de la ministre des

> Services publics et Approvisionnement Canada

>

> From: Lamothe, Colleen [mailto:Colleen.Lamothe@pmo-cpm.gc.ca]

> Sent: Friday, September 25, 2020 4:09 PM

> To: Gerasimov, Boyan (SPAC/PSPC) <boyan.gerasimov@canada.ca>;

> fitz-morris, James (SPAC/PSPC) <james.fitz-morris@canada.ca>;

> Hage-Moussa, Vanessa <Vanessa.Hage-Moussa@pmo-cpm.gc.ca>; MacKendrick,

> Andrew <Andrew.MacKendrick@pmo-cpm.gc.ca>; Hage-Moussa, Vanessa

> <Vanessa.Hage-Moussa@pmo-cpm.gc.ca>; Theis, Rick

> <Rick.Theis@pmo-cpm.gc.ca>; Holland, Alyx

> <alyx.holland@pmo-cpm.gc.ca>; Kim, Sabrina

> <Sabrina.Kim@pmo-cpm.gc.ca>; Nowers, Kathryn (HC/SC)

> <kathryn.nowers@canada.ca>; Newman, Leo (HC/SC) <leo.newman@canada.ca>

> Subject: Abbott announcement on Tuesday.

>

> Hey,

>

> Starting this chain so we are all up to speed on the latest developments regarding the Abbott deal. Below you will find a helpful one-pager we received from Health.

>

> Boyan/James - greatly appreciate it if you could please keep this group up to date over the weekend.

>

> Thanks,

> Colleen

>

> Status update on Abbott's IDNow and PanBio test devices With the input

> from PHAC's National Microbiology Laboratory (NML)

>

> <image001.jpg>

> ID Now Covid-19 V1.0

> The test

- >
- > · IDNow is a molecular test device, using a proprietary swab, which runs on a portable platform, allowing its use in point of care settings.
- >
- > · The test is an automated assay that delivers positive results in 5 minutes and takes about 15 minutes to show the negative results.
- >
- > · IDNow received an Emergency Use Authorization (EUA) in the US.
- >
- > · The test received substantial media coverage in the US when newly released for its lack of effectiveness.
- >
- > Health Canada' regulatory review
- >
- > · The Department reviewed in priority this application and worked closely with the company.
- >
- > · We are currently seeking safety and effectiveness related information and issued a request to the company on Sept 15 related to their clinical data and the use of alternative swabs.
- >
- > · Abbott informed of their intention to file a response at the end of the week of September 21.
- >
- > PHAC NML Assessment
- >
- > · IDNow was assessed by the NML. The preliminary data/analysis (based on 19 samples) were shared with HC on September 20. We will expedite the review of this information, which will complement the scientific evaluation.
- >
- > · The data appears comparable to that of the Biofire test, as an effective test.
- >
- > · NML also intends to run a cross Canada study with CPHLN much like what was done with the Spartan devices once the devices are procured.
- >
- > Procurement
- >
- > · PHAC and PSPC are in the final stages of contracting to purchase all of the 2020 Canadian allocation. Abbott is holding the supply for the federal government.
- >
- > · Provinces and territories will be engaged on September 21 at the ADM FPT Committee on Testing to initiate discussions on allocation formula to be applied to this supply.
- >
- > · Current allocation for Canada :
- >
- > o 1.1million tests; 1000 instruments in October.
- >
- > o 700,000 tests; 1,1000 instruments in November
- >
- > 700,000 tests; 400 instruments
- >